Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

11%

1 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
8(88.9%)
Phase 3
1(11.1%)
9Total
Phase 1(8)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials
NCT07252479Phase 1Recruiting

Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations

Role: lead

NCT04999384Phase 1Recruiting

First in Human, Dose Escalation Study of AN4005

Role: lead

NCT04338399Phase 3Completed

The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC

Role: lead

NCT04975958Phase 1Completed

Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors

Role: lead

NCT05358691Phase 1Withdrawn

A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants

Role: collaborator

NCT05191667Phase 1Suspended

AN0025 and Chemoradiotherapy Combination in Esophageal Cancer

Role: lead

NCT04432857Phase 1Active Not Recruiting

AN0025 and Pembrolizumab Combination in Advanced Solid Tumors

Role: lead

NCT05519059Phase 1Completed

Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer

Role: lead

NCT03152370Phase 1Completed

Preoperative Radiotherapy and E7046 in Rectum Cancer

Role: lead

All 9 trials loaded